Compugen Ltd. (NASDAQ:CGEN) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET

Company Participants

Yvonne Naughton - Head of IR and Corporate Communications

Anat Cohen-Dayag - President & CEO

Ari Krashin - Chief Financial & Operating Officer

Henry Adewoye - Chief Medical Officer

Eran Ophir - Vice President Research & Drug Discovery

Conference Call Participants

Bonnie Quach - Stifel

Mark Breidenbach - Oppenheimer

Tony Butler - Roth Capital

Daina Graybosch - SVB Leerink

Reni Benjamin - JMP Securities

Operator

Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's Second Quarter 2022 Results Conference Call. At this time, all participants are in a listen-only mode. An audio webcast of this call is available in the investor's section of Compugen's website, www.cgen.com. As a reminder, today's call is being recorded.

I would now like to introduce Yvonne Naughton, Head of Investor Relations and Corporate Communications. Yvonne, please go ahead.

Yvonne Naughton

Thank you, Joni, and thank you all for joining us on the call today. Joining me to present prepared remarks are Dr. Anat Cohen-Dayag, President and Chief Executive Officer; and Ari Krashin, Chief Financial and Operating Officer. For the Q&A session, we will also be joined by Henry Adewoye, Chief Medical Officer and Dr. Eran Ophir, Vice President Research & Drug Discovery.

Before we begin, we'd like to remind you that during this call, the company may make projections or forward-looking statements regarding future events, business outlook, development efforts and their potential outcomes, the company's discovery platform, anticipated progress, results and timelines for our programs, financial and accounting-related matters, as well as statements regarding our cash position.

We wish to caution you that such statements reflect only the company's current beliefs, expectations, and assumptions, but actual results, performance, or achievements of the company may differ materially. These statements are subject to known and unknown risks and uncertainties, and we refer you to the SEC filings for more details on these risks, including the company's most recent annual report and Form 20-F filed with the SEC on February 28, 2022. The company undertakes no obligation to update projections and forward-looking statements in the future.

With this, I now turn the call over to Anat.

Anat Cohen-Dayag

Thank you, Yvonne. Good morning, and good afternoon, everyone, and welcome to our second quarter 2022 update. Today's call will focus on the strategic decision we have taken to move the company forward with an anticipated extended cash runway through the end of 2024. I'm happy to say that we continue to execute on all fronts and have made significant progress. We now have sufficient insight to focus on two prioritized indications and wind down the existing cohort expansion studies in our current Phase 1 program.